Saswati Hazra

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer
    Saswati Hazra
    UCLA Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    PPAR Res 2008:790568. 2008
  2. pmc Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells
    Saswati Hazra
    Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Prostaglandins Leukot Essent Fatty Acids 77:51-8. 2007
  3. ncbi request reprint Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase
    Saswati Hazra
    Department of Medicine, Division of Pulmonary, Lung Cancer Research Program and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
    Mol Pharmacol 71:1715-20. 2007
  4. ncbi request reprint Inflammation and lung carcinogenesis: applying findings in prevention and treatment
    Katherine A Peebles
    David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, UCLA Lung Cancer Research Program, CA, USA
    Expert Rev Anticancer Ther 7:1405-21. 2007
  5. pmc Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer
    Felicita Baratelli
    UCLA Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Los Angeles, CA 90095, USA
    J Transl Med 6:38. 2008
  6. ncbi request reprint Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer
    Jenny T Mao
    Department of Medicine, David Geffen School of Medicine at UCLA, 37 131 CHS, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095
    Clin Lung Cancer 7:30-9. 2005
  7. pmc Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma
    Maie A St John
    Division of Head and Neck Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Clin Cancer Res 15:6018-27. 2009
  8. ncbi request reprint Adipogenic transcriptional regulation of hepatic stellate cells
    Hongyun She
    Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
    J Biol Chem 280:4959-67. 2005
  9. pmc PPAR Gamma and Hepatic Stellate Cells
    Saswati Hazra
    Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
    Comp Hepatol 3:S7. 2004
  10. doi request reprint Fat paradox of steatohepatitis
    Hidekazu Tsukamoto
    USC UCLA Research Center of ALPD and Cirrhosis, Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    J Gastroenterol Hepatol 23:S104-7. 2008

Collaborators

Detail Information

Publications12

  1. pmc The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer
    Saswati Hazra
    UCLA Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    PPAR Res 2008:790568. 2008
    ..Understanding the mechanisms underlying these effects may be helpful for designing anticancer therapies. This article summarizes recent research on the relationship between (PPARgamma), TZDs, and the COX-2/PGE2 pathways in lung cancer...
  2. pmc Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells
    Saswati Hazra
    Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Prostaglandins Leukot Essent Fatty Acids 77:51-8. 2007
    ..Here, we report that ciglitazone downregulates PGE2 in NSCLC cells...
  3. ncbi request reprint Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase
    Saswati Hazra
    Department of Medicine, Division of Pulmonary, Lung Cancer Research Program and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
    Mol Pharmacol 71:1715-20. 2007
    ..Together, these findings indicate that it is possible to use a clinically available pharmacological intervention to suppress tumor-derived PGE(2) by enhancing catabolism rather than blocking synthesis...
  4. ncbi request reprint Inflammation and lung carcinogenesis: applying findings in prevention and treatment
    Katherine A Peebles
    David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, UCLA Lung Cancer Research Program, CA, USA
    Expert Rev Anticancer Ther 7:1405-21. 2007
    ..These newly discovered molecular mechanisms in the pathogenesis of lung cancer provide novel opportunities for targeted therapy and prevention in lung cancer...
  5. pmc Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer
    Felicita Baratelli
    UCLA Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Los Angeles, CA 90095, USA
    J Transl Med 6:38. 2008
    ..These results have provided the rationale to generate a clinical grade adenoviral vector encoding CCL-21 for ex vivo transduction of human DC in order to assess intratumoral administration in late stage human lung cancer...
  6. ncbi request reprint Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer
    Jenny T Mao
    Department of Medicine, David Geffen School of Medicine at UCLA, 37 131 CHS, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095
    Clin Lung Cancer 7:30-9. 2005
    ..These preclinical data suggesting the antineoplastic effect of COX-2 inhibitors provide the basis for several ongoing pilot clinical trials to determine the feasibility of COX-2 inhibition in chemoprevention of bronchogenic carcinoma...
  7. pmc Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma
    Maie A St John
    Division of Head and Neck Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Clin Cancer Res 15:6018-27. 2009
    ..Herein we investigate the mechanisms by which interleukin-1beta (IL-1beta) might contribute to Epithelial-Mesenchymal Transition (EMT) in HNSCC...
  8. ncbi request reprint Adipogenic transcriptional regulation of hepatic stellate cells
    Hongyun She
    Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
    J Biol Chem 280:4959-67. 2005
    ..These results support the importance of adipogenic transcriptional regulation in HSC quiescence and provide a new framework for identifying novel molecular targets for the treatment of liver cirrhosis...
  9. pmc PPAR Gamma and Hepatic Stellate Cells
    Saswati Hazra
    Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
    Comp Hepatol 3:S7. 2004
    ..Expression of PPAR gamma, per se, also inhibits HSC activation. These findings support the role of PPAR gamma in reversion of activated HSC toward their quiescent state...
  10. doi request reprint Fat paradox of steatohepatitis
    Hidekazu Tsukamoto
    USC UCLA Research Center of ALPD and Cirrhosis, Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    J Gastroenterol Hepatol 23:S104-7. 2008
    ..Our recent work suggests that defective insulin signaling in activated HSC may be responsible for this paradox. Further, activated Wnt signaling is implicated in 'anti-adipogenic' stellate cell transdifferentiation in liver fibrogenesis...
  11. ncbi request reprint Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells
    Saswati Hazra
    Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
    J Biol Chem 279:11392-401. 2004
    ..In summary, our results demonstrate that the restoration of PPARgamma reverses the activated HSC to the quiescent phenotype and suppresses AP-1 activity via a physical interaction between PPARgamma and JunD...
  12. ncbi request reprint Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation
    Hidekazu Tsukamoto
    Department of Pathology, Keck School of Medicine of the University of Southern California, California, USA
    J Gastroenterol Hepatol 21:S102-5. 2006
    ..They also provide insights into the molecular basis for the use of PPAR-gamma agonists, which has been advocated for treatment of liver fibrosis...